Xvivo Perfusion AB (XVIVO.ST) stock: key figures, P/E, revenue and dividend
Health Care · Sweden · ISIN SE0004840718
Xvivo Perfusion AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 822.00 m SEK | 812.00 m SEK |
| Gross profit | 616.00 m SEK | 533.00 m SEK |
| EBIT | 88.00 m SEK | 93.00 m SEK |
| Net income | 172.00 m SEK | 25.00 m SEK |
| Diluted EPS – continuing operations | 5.44 SEK | 0.80 SEK |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
More stocks
- JPMorgan UK Small Cap Growth & Income PLC (JUGI.L)
- TFE Co. Ltd. (425420.KQ)
- Interfor Corp (IFP.TO)
- KINX Inc (093320.KQ)
- Shenzhen Minglida Precision Technology Co. Ltd. (301268.SZ)
- Fitipower Integrated Technology Inc (4961.TW)
- Xilong Chemical Co Ltd (002584.SZ)
- Sam Engineering Equipment (9822.KL)
- OK Science & Technology Co. Ltd. A (001223.SZ)
- Lingyuan Iron & Steel Co Ltd (600231.SS)
- Mingchen Health Co Ltd Class A (002919.SZ)
- BAIC Motor Corp Ltd (1958.HK)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.